Series D+
~$90m
Vaxxas secures ~A$90 million in funding to commercialise needle-free vaccination delivery technology
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.